Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.53), $0.35 worse than the analyst estimate of ($0.18).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.